Endoscopic ultrasound (EUS)-guided gallbladder drainage (EGBD) is gaining popularity as an option for the treatment of acute cholecystitis in patients who would be considered high risk for cholecystectomy [1] . EGBD has been shown to be associated with comparable technical and clinical success rates to percutaneous cholecystostomy, whilst carrying a 4.8 % -22 % risk of adverse events, including pneumoperitoneum, bile leak, and stent migration [2 -5]. Stent-induced bleeding after EGBD is however uncommon. A 95-year-old men on dabigatran with multiple comorbidities suffered from acute cholecystitis. As he was high risk for cholecystectomy, EGBD was performed. A lumen-apposing metal stent (LAMS; Spaxus, Taewoong Medical Corporation, South Korea) and a 3-cm double-pigtail stent were inserted for gallbladder drainage. He was scheduled for cholecystoscopy and stone removal 1 month later. On cholecystoscopy, a 2-cm gallstone was noted at Hartmann's pouch but could not be removed, so the LAMS was left in situ as a long-term stent. After 4 months, he was admitted with hematemesis and tarry stools; his hemoglobin had dropped to 5.9 g/dL. An urgent endoscopy was performed and it was found that his stomach was filled with blood clots (▶ Video 1). The LAMS remained in situ at the inferoposterior wall of the first part of the duodenum,
but it had caused erosion with ulceration and bleeding (▶ Fig. 1 ). The stent was removed and exchanged for a double-pigtail stent to maintain drainage of the gallbladder (▶ Fig. 2 ). Hemostatic treatment was not required. The patient's dabigatran was stopped and was not restarted. His condition stabilized and he was discharged 6 days later. Stent-induced gastrointestinal bleeding has to be considered in post-EGBD patients with anemia or signs of gastrointestinal bleeding. Further studies on the safety of anticoagulant use in patients planned for long-term stenting are required.
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